Find below a list of all Satellite Symposia of EANM’24.
The content presented on this page is constantly updated.
Find below a list of all Satellite Symposia of EANM’24.
The content presented on this page is constantly updated.
18F-PSMA-1007 PSMA PET-CT in routine clinical use – experiences and expectations
Sunday, October 20, 2024 (13:15 – 14:45)
Hall X1-X4
Chair: F.Giesel
Speaker (presentation time 12-15 min):
Points to be covered:
Content/Abstracts/Speakers will be mentioned here as soon as confirmed.
AGENDA – OVERVIEW
Time | Session Title |
13:15-13:25 (10 minutes) |
Welcome & Introduction
|
13:25-13:50 (25 minutes) |
Expert Insights: Current Status of Theranostics Deployment in Daily Practice
|
13:50-14:25 (35 minutes) |
Panel Discussion: Challenges and Opportunities for Improved HCS Readiness |
14:25-14:35 (10 minutes) |
Audience Q&A Session |
14:35-14:45 (10 minutes) |
Wrap-up & Meeting Close
|
This symposium is organized and funded by Novartis in the context of EANM 2024, in Germany. This scientific program and/or material was developed for use outside of the US, intended solely for non-US physicians and pharmacists, and is to be used in accordance with local laws and regulations. The aim of this medical symposium is scientific, educational and not promotional. This scientific information may include data/ information on investigational uses of
compounds/drugs that have not yet been approved by regulatory authorities. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country.
Speakers: Dr. Arthur J.A.T. Braat (Moderator), Dr. Marco Maccauro, Dr. Cigdem Soydal
Presentations:
Chair: Prof. Viktor Grunwald
Time | Session Title | Presenter |
13:00-13:10 (10 minutes) |
Welcome & Introduction to
Patient-Centric Innovations: The Impact of Rhenium-SCT® on Non-Melanoma Skin Cancer |
|
13:10-13:30 (20 minutes) |
“Rhenium-188 Epidermal Radioisotope Therapy: Long-term Clinical Experience from S.Orsola Hospital, Bologna Italy“ | Prof. Paolo Castellucci Nuclear Medicine Physician, Italy |
13:30-13:50 (20 minutes) |
“Patient-Reported Outcomes Show Significant Quality of Life Improvements, High Success Rate, and Outstanding Aesthetic Results with Rhenium-SCT® in the EPIC-Skin interim analysis“ | Prof. Siroos Mirzaei Head of Nuclear Medicine, Austria |
13:50-14:10 (20 minutes |
“Interim Analysis of the EPIC-Skin® Study Highlights Innovative Application Method and High Efficacy and Safety of Rhenium Skin Cancer Therapy® for Non-melanoma Skin Cancer“ | A/Prof. Joe Cardaci Nuclear Medicine Physician, Australia |
14:10-14:30 (20 minutes) |
Audience Q&A Session | |
14:30-14:40 (10 minutes) |
Wrap-up & Meeting Close |
Our speakers who are leaders in the field of prostate cancer will share their clinical experience:
Symposium summary:
Nowadays, prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is taking a central role in the daily management of patients with prostate cancer.
Our speakers will focus on the role PSMA PET radiopharmaceuticals play in their practice – from the perspective of a urologist and nuclear medicine physician.
Embark on a journey to explore new clinical frontiers with PET technology at this year’s symposium, proudly sponsored by United Imaging. We will delve into pioneering advancements in next-generation molecular imaging technologies, including the Total-body PET/CT uEXPLORER, the 148-cm whole-body PET/CT uMI Panorama GS and HD TOF PET/MR uPMR 790. Join us at the 2024 EANM Annual Conference to discover the diverse and exciting future of molecular imaging.
Speakers:
Format: Plenary presentations followed by a panel discussion
Moderator: Prof K. Herrmann, Essen University Hospital, Germany
Advancing cardiac PET accessibility: the role of novel tracers
Prof. Francois Rouzet, Head of Nuclear Medicine Department, Bichat Hospital, France
Dr. Arthur Braat, M.D. Ph.D. University Medical Center Utrecht, The Netherlands
Leveraging new technology to elevate nuclear medicine imaging
Prof. Louise Emmett, St Vincent’s Hospital, Sydney, Australia
Prof. Jan Abrahamsen, Regional Hospital Viborg, Denmark
Additional panelists:
Prof. Irene Burger, Kantonsspital Baden, Switzerland
Prof. Mike Sathekge, NuMeRI, South Africa
Prof. Andrei Iagaru, USA
Panel Discussion about the future of Molecular Imaging
Agenda:
13:00
Registration and Lunch
13:15
Welcome and Introduction
13:20
The Lived Experience of mCRPC
13:45
Treating the Condition
14:15
Team-Based Care and Shared-Decision Making in the Delivery of Care for mCRPC
14:35
Closing Remarks and Q&A
Speakers:
Alison Birtle, MD, MBBS, FRCR, FRCP
Consultant Clinical Oncologist
The Rosemere Cancer Centre
Lancashire Teaching Hospital
Professor
University of Manchester
University of Central Lancashire
Preston, United Kingdom
Ray McDermott, MD, PHD
Clinical Professor
Consultant Medical Oncologist
St. Vincent’s University Hospital and Cancer Trials
Dublin, Ireland
Kambiz Rahbar, MD
Professor Nuclear Medicine
Consultant/Attending Nuclear Oncology
West German Cancer Center
Department of Nuclear Medicine
University Hospital Münster
Münster, Germany
Tony Collier, BEM
Patient Representative
Trustee and Vice-Chair
Tackle Prostate Cancer
United Kingdom
Activity Overview:
Despite the significant advances in the treatment options available, metastatic castration-resistant prostate cancer (MCRPC) remains a fatal disease, with a 5-year survival rate of only 30%. The treatment armamentarium for these patients currently includes antiandrogens, chemotherapies, immunotherapy, targeted agents, and radioligand therapy. In this symposium experts will explore new approaches using radioligand therapy, reviewing the latest clinical data and considerations on translating this into the clinic. They will also discuss the importance of team-based care and the role of shared decision-making in ensuring that patients receive the best care available, as well as a deeper look at the patient journey with prostate cancer.
This educational activity is intended for a global audience of oncologists, radiologists, urologists, surgeons, and any other healthcare specialists involved in the care of patients with prostate cancer.
Medscape, LLC designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Supported by an independent educational grant from Bayer.
For more information, visit www.medscape.org/symposium/radioligands-mcrpc
PeerView EBAC/CME/AAPA/IPCE Symposium
Agenda:
Presenters:
Prof. Dr. med. Alexander Drzezga
Professor and Chair
Department of Nuclear Medicine
University Hospital Cologne
Jülich, Germany
Satoshi Minoshima, MD, PhD
Anne G. Osborn Chairman and Professor
Department of Radiology and Imaging Sciences
Spencer Fox Eccles School of Medicine
University of Utah
Salt Lake City, Utah
Prof. Silvia Daniela Morbelli, MD, PhD
Full Professor of Nuclear Medicine
Città della Scienza e della Salute di Torino
University of Turin
Turin, Italy
Summary:
Amyloid-targeting therapies (ATTs) for Alzheimer’s disease (AD) have begun to change the standard of care for early-stage AD by allowing for more targeted intervention aimed at reducing the accumulation of amyloid-beta (Aβ) plaques in the brain. Successful implementation of ATTs hinges on early biomarker testing (eg, amyloid PET imaging, CSF, plasma testing) to confirm the presence of Aβ plaques. As ATTs edge closer to regulatory approval in Europe, an increased need for molecular diagnosis of AD is expected to significantly increase radiology practice volumes.
PeerView’s Case Conference live symposium will convene a panel of leading nuclear medicine experts to blend case-based discussion with short seminars to illustrate how to utilize validated and emerging neuroimaging biomarkers to facilitate the early diagnosis of AD. Learners will gain a deeper understanding of the complex diagnostic challenges associated with early-stage AD.
This EBAC/CME/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.
PVI, PeerView Institute for Medical Education is an EBAC® accredited provider since 2023.
This activity is supported by an educational grant from Lilly.
Register today at PeerView.com/24AD-Live!
Meeting Objectives:
Timings | Presentation title | Suggested faculty (TBC) |
15 minutes | Understanding cardiac amyloidosis and the importance of early recognition and treatment | TBC |
20 minutes | Advanced imaging techniques and the role of non invasive diagnosis of ATTR-CM | TBC |
15 minutes | Navigating diagnostic complexities for cardiac scintigraphy in ATTR-CM | TBC |
10 minutes | Q&A | All, moderated by Chair |